Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Introduction: Apixaban dosing in atrial fibrillation (AF) is 5 mg BID or 2.5 mg BID in patients
with≥ 2 dose-reduction criteria: age> 80 years, weight< 60 kg, or creatinine> 1.5 mg/dl …

Background Recent guidelines caution against the use of non-vitamin K antagonists oral
anticoagulants (NOACs) in patients with extremely high body weight (≥ 120 kg) due to lack …

Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …

Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

Abstract Background Direct oral anticoagulants (DOACs) have become favorable choices for
anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non …